Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Microbiol Spectr ; 9(2): e0005521, 2021 10 31.
Article in English | MEDLINE | ID: covidwho-1467670

ABSTRACT

Bacterial-viral interactions in saliva have been associated with morbidity and mortality for respiratory viruses such as influenza and SARS-CoV. However, such transkingdom relationships during SARS-CoV-2 infection are currently unknown. Here, we aimed to elucidate the relationship between saliva microbiota and SARS-CoV-2 in a cohort of newly hospitalized COVID-19 patients and controls. We used 16S rRNA sequencing to compare microbiome diversity and taxonomic composition between COVID-19 patients (n = 53) and controls (n = 59) and based on saliva SARS-CoV-2 viral load as measured using reverse transcription PCR (RT-PCR). The saliva microbiome did not differ markedly between COVID-19 patients and controls. However, we identified significant differential abundance of numerous taxa based on saliva SARS-CoV-2 viral load, including multiple species within Streptococcus and Prevotella. IMPORTANCE Alterations to the saliva microbiome based on SARS-CoV-2 viral load indicate potential biologically relevant bacterial-viral relationships which may affect clinical outcomes in COVID-19 disease.


Subject(s)
Bacteria/classification , COVID-19/pathology , Microbial Interactions/physiology , SARS-CoV-2/isolation & purification , Saliva/microbiology , Bacteria/genetics , Dysbiosis/microbiology , Female , Humans , Male , Microbiota/genetics , Middle Aged , Nasopharynx/microbiology , RNA, Ribosomal, 16S/genetics , Viral Load
2.
Gastroenterology ; 161(1): 360-361, 2021 07.
Article in English | MEDLINE | ID: covidwho-1331406
3.
Gastroenterology ; 161(1): 360-361, 2021 07.
Article in English | MEDLINE | ID: covidwho-1294518
4.
Gastroenterology ; 161(1): 360-361, 2021 07.
Article in English | MEDLINE | ID: covidwho-1246434
5.
Gastroenterology ; 160(5): 1900-1901, 2021 04.
Article in English | MEDLINE | ID: covidwho-1189303
6.
Clin Gastroenterol Hepatol ; 19(7): 1402-1409.e1, 2021 07.
Article in English | MEDLINE | ID: covidwho-807692

ABSTRACT

BACKGROUND & AIMS: Our understanding of outcomes and disease time course of COVID-19 in patients with gastrointestinal (GI) symptoms remains limited. In this study we characterize the disease course and severity of COVID-19 among hospitalized patients with gastrointestinal manifestations in a large, diverse cohort from the Unites States. METHODS: This retrospective study evaluated hospitalized individuals with COVID-19 between March 11 and April 28, 2020 at two affiliated hospitals in New York City. We evaluated the association between GI symptoms and death, and also explored disease duration, from symptom onset to death or discharge. RESULTS: Of 2804 patients hospitalized with COVID-19, the 1,084 (38.7%) patients with GI symptoms were younger (aOR for age ≥75, 0.59; 95% CI, 0.45-0.77) and had more co-morbidities (aOR for modified Charlson comorbidity score ≥2, 1.22; 95% CI, 1.01-1.48) compared to those without GI symptoms. Individuals with GI symptoms had better outcomes, with a lower likelihood of intubation (aHR, 0.66; 95% CI, 0.55-0.79) and death (aHR, 0.71; 95% CI, 0.59-0.87), after adjusting for clinical factors. These patients had a longer median disease course from symptom onset to discharge (13.8 vs 10.8 days, log-rank p = .048; among 769 survivors with available symptom onset time), which was driven by longer time from symptom onset to hospitalization (7.4 vs 5.4 days, log-rank P < .01). CONCLUSION: Hospitalized patients with GI manifestations of COVID-19 have a reduced risk of intubation and death, but may have a longer overall disease course driven by duration of symptoms prior to hospitalization.


Subject(s)
COVID-19 , Gastrointestinal Diseases/virology , COVID-19/complications , COVID-19/diagnosis , COVID-19/mortality , Comorbidity , Female , Hospitalization , Humans , Male , New York City , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL